Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valproic acid + expanded cord blood stem cells
- Development stage
- Phase 1
- Lead developer
- University of Illinois Chicago
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Valproic acid + expanded cord blood stem cells refers to an experimental cell therapy product where umbilical cord blood (UCB) is cultured ex vivo with the small molecule valproic acid (VPA) to increase the population of hematopoietic stem and progenitor cells (HSPCs). Valproic acid acts as a histone deacetylase (HDAC) inhibitor, which modifies the epigenetic state of the cells to promote self-renewal and inhibit differentiation, effectively expanding the number of CD34+ cells available for transplantation. This approach aims to overcome the significant limitation of cord blood transplantation—the low absolute number of stem cells in a single unit—thereby accelerating hematopoietic recovery and improving clinical outcomes for patients with high-risk hematologic malignancies who lack a matched bone marrow donor.
- Other names
- VPA-expanded cord bloodvalproic acid-expanded hematopoietic stem cellsVPA-expanded CD34+ cellsVPA-UCB
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC8 (Histone Deacetylase 8)GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on valproic acid + expanded cord blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valproic acid + expanded cord blood stem cells.